Compare NetApp Inc. (NTAP) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Novartis AG — how do they compare? NetApp Inc. trades at $233.53 (market cap $45.38B), while Novartis AG trades at $143.12 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5.9× NetApp Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Novartis AG for 82 Days on average.
| NTAP | NVS | |
|---|---|---|
Market Cap | $45.38B | $268.57B |
Volume | 2,264,311 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $235.84 | $168.62 |
52-Week Low | $94.11 | $121.80 |
Typical Hold Time | 57 Days | 82 Days |
Enterprise Value | $44.34B | $309.89B |
Dividend Yield | 0.9% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $235.84, up 3.23% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Fundamentally, the company maintains robust profitability with 70.63% gross margins and 19.19% net income margin. Recent AI infrastructure partnerships with Oracle, SAP, and Supermicro position NTAP for growth in the expanding AI data storage market.
Outlook remains positive with AI-driven demand creating new revenue opportunities, though valuation multiples appear elevated. Key risks include competitive pressures in cloud storage and potential market volatility. Analyst consensus leans neutral with 50.7% hold ratings, suggesting cautious optimism amid strong technical performance.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
